BACKGROUNDTreatment of functional dyspepsia is often challenging due to involvement of multiple pathophysiological mechanisms and heterogeneous group of symptoms for the patients. Though several prokinetic drugs have been tried, none of them have established long-term efficacy and safety. Levosulpiride is a newer prokinetic drug with D2 blocking and 5HT4 agonistic action, which was compared with placebo for assessing its efficacy and safety.

No abstract

No abstract